ZIOPHARM Oncology Inc. (ZIOP) has fallen 5.19% Monday In Premarket Trading

Monday, December 20, 2021 07:25 AM | InvestorsObserver Analysts

Mentioned in this article

ZIOPHARM Oncology Inc. (ZIOP) has fallen 5.19% Monday In Premarket Trading

ZIOPHARM Oncology Inc. (ZIOP) has fallen Monday morning, with the stock losing -5.19% in pre-market trading to 1.28. ZIOP's short-term technical score of 66 indicates that the stock has traded more bullishly over the last month than 66% of stocks on the market. In the Biotechnology industry, which ranks 134 out of 146 industries, the stock ranks higher than 88% of stocks. ZIOPHARM Oncology Inc. has fallen 5.59% over the past month, closing at $1.38 on November 22. During this period of time, the stock fell as low as $1.18 and as high as $1.45. ZIOP has an average analyst recommendation of Buy. The company has an average price target of $3.17.

ZIOP has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on ZIOP!

See Full ZIOP Report

ZIOPHARM Oncology Inc. has a Long-Term Technical rank of 14. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 86% of the market scoring higher. In the Biotechnology industry which is number 139 by this metric, ZIOP ranks better than 36% of stocks.

Important Dates for Investors in ZIOP:

-ZIOPHARM Oncology Inc. is set to release earnings on 2/6/2022. During their last earnings release the company posted EPS of $-0.43. -We do not have a set dividend date for ZIOPHARM Oncology Inc. at this time. Click Here To Get The Full Report on ZIOPHARM Oncology Inc. (ZIOP)